若生智能
Drug Database
BE

bevacizumab (BP 01 / Bevqolva / BP01)

✓ Approved

Aurobindo Pharma Limited · VEGFA · 单克隆抗体

什么是 bevacizumab？

bevacizumab 是一种单克隆抗体，由Aurobindo Pharma Limited研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名BP 01, Bevqolva, BP01
公司Aurobindo Pharma Limited
药物类别单克隆抗体, 抗体
分子靶点VEGFA
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Aurobindo Pharma Limited

作用机制

分子靶点

bevacizumab 作用于 1 个分子靶点：

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

bevacizumab 针对 9 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Renal cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Colorectal cancer✓ Approved

注册免费账户还可查看另外 4 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedTherapeutic advances in gastroenterology2026-08-05

Pulmonary diffusion abnormalities in patients with inflammatory bowel disease: A longitudinal study.

Maisonneuve Hugo H, Caron Benedicte B, Guillaumot Anne A, Poussel Mathias M et al.

Impaired diffusing capacity of the lung for carbon monoxide (DLCO) has been frequently described among patients with inflammatory bowel diseases, but longitudinal data of DLCO impairment and its association with IBD activity remain unclear. To describe the longitudinal report of prevalence and clinical characteristics of chronic DLCO impairment among patients with IBD reporting respiratory symptoms. We conducted a prospective single-center study including consecutive patients with confirmed IBD and respiratory symptoms. Patients underwent longitudinal evaluation with chest CT scans and pulmonary function tests. Among 75 patients with DLCO measurements, 12 (16%) showed persistently reduced DLCO over a median follow-up of 26.9 [IQR 24.9-30.6] months. Median DLCO was 63.4% of predicted value. All patients had mild or inactive IBD and were on biologics. Imaging abnormalities were mild and did not explain the DLCO reduction. Chronic DLCO impairment was observed in 16.0% of IBD patients and no obvious association with clinically active IBD was observed in this selected symptomatic cohort.

PMID 42553422
阅读全文 →
PubMedACR open rheumatology2026-08-05

Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor-Induced Autoimmunity.

Hu Xizi X, Ryoo Ji Eun JE, Henick Brian S BS, Mor Adam A

The rapid integration of immune checkpoint inhibitors (ICIs) into standard oncology protocols has birthed a new frontier in clinical rheumatology: immune-related adverse events (irAEs). By disrupting the programmed cell death-1 (PD-1)/PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) axes to restore antitumor T cell activity, these therapies inadvertently breach peripheral tolerance. This results in a spectrum of de novo autoimmune and inflammatory syndromes that frequently mimic established rheumatic diseases, including inflammatory arthritis and myositis. Although ICIs have revolutionized survival outcomes, the resultant irAEs pose a significant clinical challenge, affecting nearly 50% of patients and often necessitating the expertise of rheumatologists for management. This manuscript explores the unique rheumatologic phenotype of ICI-induced toxicities, emphasizing the urgent need for a shift from broad-spectrum glucocorticoid use toward targeted, mechanism-driven therapies that do not compromise the abscopal antitumor effect. We review the current landscape of clinical trials investigating the repurposing of traditional disease-modifying antirheumatic drugs and advanced biologics. Specifically, we discuss the efficacy and safety of tumor necrosis factor-alpha inhibitors, interleukin-6 receptor antagonists, and JAK inhibitors in the context of steroid-refractory irAEs. We further analyze the molecular commonalities between idiopathic autoimmune diseases and ICI-induced inflammation. As the patient population receiving ICIs grows, the rheumatologist's role as a co-manager is increasingly essential. This review highlights the need for standardized grading and treatment algorithms for rheumatologic irAEs and advocates collaborative research to separate immunotherapy toxicities from its oncological benefits.

PMID 42552647
阅读全文 →
PubMedFrontiers in pharmacology2026-08-05

Severe non-atopic prurigo nodularis in an otherwise healthy elderly patient: rapid multidimensional response to dupilumab.

Ventre Alessandra A, Nuccio Federica F, Gangemi Sebastiano S, Ricciardi Luisa L

Prurigo nodularis (PN) is a chronic neuroimmune skin disorder characterized by intensely pruritic nodules, severe impairment of quality of life and significant psychosocial burden. Prior to the approval of targeted therapies, management relied on conventional agents with limited efficacy. Recent evidence of its neuroimmune pathogenesis have led to the approvement of targeted biologics. Dupilumab, a human monoclonal antibody targeting IL-4/IL-13-axis, has been the first targeted therapy approved for PN. We report a 75-year-old woman presenting with severe, treatment-naïve generalized pruritus (IGA PN-S 4; NRS 9/10; DLQI 21) with extensive nodular involvement of the trunk and extremities, complete sleep deprivation and important anxiety and depression (HADS.A 12; HADS-D 11). Following diagnosis of PN, treatment with dupilumab (600 mg loading dose, then 300 mg every 2 weeks) was initiated in October 2025. At approximately 6 weeks, marked pruritus reduction (NRS 3) and sleep restoration were observed. Progressive improvement continued over time. At 4 months follow-up, complete remission was nearly achieved (NRS 1, IGA PN-S 1, DLQI 2, HADS-A 4, HADS-D 3), with no adverse events reported. This case corroborates and extends the existing evidence on dupilumab efficacy in the treatment of moderate-to-severe PN, with particularly rapid and comprehensive responses across pruritus, skin lesions, sleep and psychosocial outcomes in an elderly patient, through IL-4/IL-13 inhibition. Our findings support dupilumab as a safe and effective targeted option for severe PN, also in older patients where conventional systemic therapies, such as corticosteroids or immunosuppressants, carry a high risk of adverse effects.

PMID 42553303
阅读全文 →
PubMedTaiwan journal of ophthalmology2026-08-04

Retinopathy of prematurity epidemiology and treatment trend in a tertiary medical center in Taiwan: From 2016 to 2023.

Tseng Yi-Hsuan YH, Wu Pei-Liang PL, Kang Eugene Yu-Chuan EY, Chen Kuan-Jen KJ et al.

To investigate the recent 8-year epidemiology of retinopathy of prematurity (ROP) and treatment modalities in Taiwan. A retrospective study was conducted from 2016 to 2023, using data from Chang Gung Memorial Hospital, Linkou, Taiwan, and enrolling 2078 premature babies who were screened for ROP. The incidence of ROP, type 1 ROP, and initial treatment were analyzed. ROP developed in 671 of the 2078 infants (29.7%), and type 1 ROP was present in 195 infants (9.4%). A declining trend was observed in the number of ROP screenings among premature infants (P = 0.02). The proportion of type 1 ROP decreased significantly from 12.13% in 2016 to 5.0% in 2023 (P < 0.01). Antivascular endothelial growth factor (VEGF) was chosen in 97% and 93.2% of the initial and overall treatments, respectively, with laser mainly used as a secondary treatment. Bevacizumab was the most frequently selected option among the three available anti-VEGF drugs. The incidence of ROP between 2016 and 2023 showed no significant change. The proportion of type 1 ROP decreased during this period. Anti-VEGF was chosen as the initial treatment, and bevacizumab was the most frequently used agent.

PMID 42549255
阅读全文 →
PubMedAnnals of dermatology2026-08-04

Factors Associated With PASI90 Maintenance Without Flare-Up and Predictors of Biologics Discontinuation in Psoriasis: Two-Center Retrospective Cohort Study in Korea.

Choi Mi Soo MS, Yeom Kyujin K, Jung Seung-Won SW, Hong Seung Phil SP et al.

Biologics targeting key cytokines have enabled near-complete clearance in psoriasis treatment. As 90% reduction in the Psoriasis Area and Severity Index (PASI90) emerges as a meaningful goal of treatment, maintaining PASI90 without flare-up has become important. To identify factors associated with PASI90 maintenance for ≥1 year without flare-up and predictors of drug discontinuation. This multicenter retrospective cohort study included moderate-to-severe plaque psoriasis patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, guselkumab, or risankizumab (2010-2022). Treatment courses were defined as "Episodes." Patients with ≥2 years of therapy were analyzed. Relative risks (RR) for PASI90 maintenance were estimated using generalized linear mixed models, and Cox proportional hazards models assessed drug discontinuation. Among 136 patients (189 episodes), 40.1% of 162 eligible episodes achieved PASI90 maintenance without flare-up for ≥1 year. Secukinumab significantly increased the likelihood of PASI90 maintenance (RR, 2.1; 95% confidence interval [CI], 1.27-3.49). Body mass index (BMI) <30 and first biologic episode showed favorable with only trend toward significance. Psoriasis Area and Severity Index response at week 16 and first assessment strongly predicted maintenance (area under the curve, 0.80-0.82). Regarding drug discontinuation, drug were discontinued in 28.6% of episodes; BMI ≥30, family history of psoriasis, and adalimumab (hazard ratio, 4.50; 95% CI, 1.57-12.90 vs. ustekinumab) were associated with higher risk of drug discontinuation. Secukinumab, lower BMI, and biologic-naïve status favored durable PASI90 without flare-up. Obesity, family history, and adalimumab predicted drug discontinuation. Early treatment response strongly predicted long-term efficacy.

PMID 42547477
阅读全文 →
PubMedBeyoglu eye journal2026-08-04

Efficacy and Safety of Intravitreal Triamcinolone Acetonide Alone or Combined with Intravitreal Bevacizumab in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.

Diracoglu Aynur A, Agin Abdullah A, Cakir Mehmet M, Demirok Ahmet A

To compare the efficacy and safety of intravitreal triamcinolone acetonide (IVTA) monotherapy versus combined intravitreal triamcinolone acetonide and bevacizumab (IVTA+IVB) therapy in the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). In this retrospective study, 66 eyes of 65 patients with BRVO-related macular edema were evaluated. Patients were divided into two groups: IVTA monotherapy (n=37) and IVTA+IVB combination therapy (n=29). Central macular thickness (CMT), best-corrected visual acuity (BCVA), and intraocular pressure (IOP) were measured at baseline, week 1, and months 1, 3, and 6 after injection. Both groups demonstrated significant improvements in BCVA and reductions in CMT compared with baseline (p<0.001), with no statistically significant differences between the groups at any follow-up time point. IOP was significantly elevated in the IVTA group at several time points (p<0.05), while the combination group showed stable IOP levels. New-onset glaucoma developed in 8 patients in the IVTA group and only 1 patient in the combination group. No serious ocular complications occurred in either group. Both treatment regimens provided comparable anatomical and visual improvements; however, combination therapy was associated with a more favorable safety profile. Although the use of IVTA has declined in contemporary clinical practice in favor of intravitreal dexamethasone implants, this study suggests that IVTA alone or in combination may still offer a viable and cost-effective alternative in regions where access to current therapies is limited or in low-resource settings.

PMID 42549240
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多bevacizumab